Mycobacterium tuberculosis Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Mycobacterium tuberculosis Infections – Drugs In Development, 2023’, provides an overview of the Mycobacterium tuberculosis Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mycobacterium tuberculosis Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mycobacterium tuberculosis Infections
- The report reviews pipeline therapeutics for Mycobacterium tuberculosis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mycobacterium tuberculosis Infections therapeutics and enlists all their major and minor projects
- The report assesses Mycobacterium tuberculosis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mycobacterium tuberculosis Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mycobacterium tuberculosis Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abera Bioscience ABAdjuTec Pharma AS
Agency for Science
Technology and Research
Akagera Medicines Inc
Albert Einstein College of Medicine
Alopexx Inc
Archivel Farma SL
Astellas Pharma Inc
AstraZeneca Plc
Atomwise Inc
Austrianni GmbH
Bill & Melinda Gates Medical Research Institute
BioLingus AG
BioNTech SE
Bioversys AG
Bristol-Myers Squibb Co
Brown University
Butantan Institute
California Institute for Biomedical Research
CanSino Biologics Inc
Central Drug Research Institute
Centre d'Immunologie et des Maladies Infectieuses Paris
Changzhou Yinsheng Pharmaceutical Co Ltd
Chengdu Keen Biotechnology Co Ltd
Chinese Academy of Medical Sciences and Peking Union Medical College
Chongqing Zhifei Biological Products Co Ltd
Collaborations Pharmaceuticals Inc
Colorado State University
Consegna Pharma Inc
Creighton University
Crestone Inc
Daiichi Sankyo Co Ltd
Dartmouth-Hitchcock Medical Center
Demuris Ltd
Eisai Co Ltd
Eli Lilly and Co
Emory University School of Medicine
Enyo Pharma SA
EpiVax Inc
Evoq Nano Inc
Evotec SE
Exscientia Plc
Eyam Vaccines and Immunotherapeutics Ltd
EyeGene Inc
Fimbrion Therapeutics Inc
Foundation For Neglected Disease Research
Gamaleya Federal Research Center of Epidemiology and Microbiology
GC Biopharma Corp
Genexine Inc
GENUONE Sciences Inc
George Washington University
Global Alliance for TB Drug Development
Globeimmune Inc
Griffith University
GSK plc
Guangzhou Egg Biotechnology Co Ltd
HanaVax Inc
Harvard University
Helmholtz Centre for Infection Research
Hsiri Therapeutics LLC
ILiAD Biotechnologies LLC
ImCheck Therapeutics SAS
Immodulon Therapeutics Ltd
Immunitor Inc
ImmunoBiology Ltd
Infectex
Innovare R & D SA De CV
International AIDS Vaccine Initiative Inc
Jiangsu Recbio Technology Co Ltd
Johns Hopkins University
Johns Hopkins University School of Medicine
Johnson & Johnson
Kangzhong Beijing Biological Technology Co Ltd
Korea Research Institute of Chemical Technology
L2 Diagnostics LLC
Lead Discovery Center GmbH
LegoChem Biosciences Inc
LifeArc
Linnane Pharma AB
Longhorn Vaccines and Diagnostics LLC
Ludwig-Maximilians-University Munich
Massey University
Medicines Development for Global Health Ltd
Merck & Co Inc
MetalloPharm LLC
Microbiotix Inc
Moderna Inc
Monash University
Mountain Valley MD Holdings Inc
Mycosynthetix Inc
Nearmedic Plus
NES Biotechnology Co Ltd
Neuro Horizon Pharma LLC
NovoBiotic Pharmaceuticals LLC
Nykode Therapeutics ASA
Oak Therapeutics Inc
Opal Biosciences Ltd
Otsuka Pharmaceutical Co Ltd
Pai Life Sciences Inc
Palacky University Olomouc
Palisades Therapeutics
Pasteur Institute
Pathens Inc
PDS Biotechnology Corp
PeptiDream Inc
Pfizer Inc
Pharmapraxis
Pharmasyntez
Piramal Pharma Ltd
Primetime Life Sciences LLC
Princeton University
Protibea Therapeutics Inc
Purdue University
Quratis Inc
QureTech Bio AB
Qurient Co Ltd
Research Institute of Influenza
Royal College of Surgeons Ireland
Rutgers The State University of New Jersey
Sanofi
Saurashtra University
Scientific Center for Anti-Infectious Drugs
Sentan Pharma Inc
Seoul National University
Sequella Inc
Serum Institute of India Pvt Ltd
Shanghai H&G Biotech
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shanghai Public Health Clinical Center
Sichuan University
Southwest University
SPbNIIVS FMBA of Russia
Spero Therapeutics Inc
Sphaera Pharma Pte Ltd
SpinCeutica Inc
St. George's University of London
St. George’s University
Standigm Inc
Statens Serum Institut
Stony Brook University
Target Medicals
Tarn Biosciences Inc
Technical University of Munich
Texas Biomedical Research Institute
Texas Tech University Health Sciences Center
The Broad Institute Inc
The Fifth People's Hospital of Suzhou
The Scripps Research Institute
The University of Adelaide
The University of British Columbia
The University of Manchester
Thirty Respiratory Ltd
Tibet Rhodiola Pharmaceutical Holding Co Ltd
TVAX Biomedical Inc
Tydock Pharma Srl
UAB Minority Health and Health Equity Research Center
Univeristy of Zaragoza
University College London
University of Auckland
University of Cape Town
University of Central Florida
University of Dundee
University of Georgia
University of Kansas
University of Kentucky
University of Milan
University of Nebraska Medical Center
University of Oxford
University of Queensland
University of Tennessee Research Foundation
University of Toledo
University of Wisconsin Madison
University of Zurich
Uvax Bio LLC
Vanderbilt University
Vaxil Bio Therapeutics Ltd
Vaxinano SE
Vaxine Pty Ltd
Vichem Chemie Research Ltd
Vir Biotechnology Inc
Wuhan University
Zata Pharmaceuticals Inc